You are required to be logged in to access the full website
Click here if you have forgotten your username or password
Therapy Areas
14 April 2026 - CrossBridge Bio Inc, a pre-clinical biotechnology company developing next-generation dual-payload antibody-drug conjugates (ADCs), announced on Tuesday that it has entered into a definitive agreement to be acquired by pharmaceutical c...
14 April 2026 - hVIVO plc (AIM:HVO), a specialist in conducting human challenge trials, announced on Tuesday that it has signed a clinical trial agreement with Traws Pharma (NASDAQ:TRAW), a clinical-stage biopharmaceutical company developing novel th...
14 April 2026 - US precision medicine oncology company IDEAYA Biosciences Inc (NASDAQ:IDYA) and French pharmaceutical company Servier announced on Monday positive topline results from their Phase 2/3 registrational trial, OptimUM-02, evaluating darov...
14 April 2026 - Australian oncology company Kazia Therapeutics Limited (Nasdaq:KZIA) announced on Monday the in-licensing of a first-in-class SETDB1-targeted epigenetic drug development platform from QIMR Berghofer.The platform includes use of an AI-...
14 April 2026 - Chinese pharmaceutical company Sichuan Kelun-Biotech Biopharmaceutical Co Ltd (HK:6990) announced on Monday that results from both the ovarian cancer cohort and the cervical cancer cohort of a Phase II study of the TROP2 ADC sacituzum...
13 April 2026 - Denmark-based biotechnology company Genmab A/S (Nasdaq: GMAB) reported on Monday that its Phase 1/2 RAINFOL-01 data showed that rinatabart sesutecan (Rina-S) in combination with bevacizumab demonstrated a tolerable safety profile in p...
13 April 2026 - Biopharmaceutical company GSK plc (LSE: GSK) (NYSE: GSK) on Monday announced positive results from its global phase I BEHOLD-1 trial evaluating mocertatug rezetecan (Mo-Rez), a B7-H4-targeted antibody-drug conjugate, in gynaecological...